Ann: Phase 1B ADVENT-AML trial to be presented at ASH meeting, page-4

"The study, which has received IND clearance by the FDA and is expected to open to enrollment by year end 2023"

It seems that the trial is recruiting patients now:


https://clinicaltrials.gov/study/NCT05834244

Whilst the status has been updated on 26/10/23, the company announcement above dated 20/11/23 suggested it hasn't at that time.

I found the following link to apply for the trial:



https://www.withpower.com/trial/phase-1-leukemia-8-2023-2f24f

The ASH poster can be found here:
https://ash.confex.com/ash/2023/webprogram/Paper182885.html



A comment from PI Dr Abhishek Maiti:
"Furthermore, this clinical trial can potentially transform the standard treatment approach as well as landscape of emerging therapies for older, unfit, or transplant-ineligible patients."
https://gatewaycr.org/for-researchers/clinical-trials/azacitidine-venetoclax-and-nk-cells-in-newly-daignosed-older-unfit-aml/